Allogene Therapeutics, Inc.
ALLO
$2.13
$0.073.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 11.77% | -8.12% | |||
| Gross Profit | -11.77% | 8.12% | |||
| SG&A Expenses | 2.30% | 0.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.70% | -5.56% | |||
| Operating Income | -8.70% | 5.56% | |||
| Income Before Tax | -9.78% | 6.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.78% | 6.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.78% | 6.26% | |||
| EBIT | -8.70% | 5.56% | |||
| EBITDA | -9.85% | 5.88% | |||
| EPS Basic | -3.26% | 7.94% | |||
| Normalized Basic EPS | -3.26% | 7.90% | |||
| EPS Diluted | -3.26% | 7.94% | |||
| Normalized Diluted EPS | -3.26% | 7.90% | |||
| Average Basic Shares Outstanding | 6.31% | 1.80% | |||
| Average Diluted Shares Outstanding | 6.31% | 1.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||